Ceftriaxone Industry Research 2024: Effective Treatment of Multi-Drug Resistant Infections Bolsters Growth - Global Forecasts to 2032
June 28, 2024 11:31 ET
|
Research and Markets
Dublin, June 28, 2024 (GLOBE NEWSWIRE) -- The "Global Ceftriaxone Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts,...
Ceftriaxone Market Size Worth USD 2.2 billion by 2031, Expanding at a CAGR of 2.9% | Exclusive Report by Transparency Market Research
August 18, 2023 08:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global ceftriaxone market is projected to flourish at a CAGR of 2.9% from 2022 to 2031....
Rafarma Pharmaceuticals (RAFA) Commences Preparation of Audited Financials
May 12, 2014 09:15 ET
|
Rafarma Pharmaceuticals, Inc.
MOSCOW, May 12, 2014 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. (Pink Sheets:RAFA) has commenced a formal audit to provide additional transparency in its public filings with a forward view to...
Rafarma (RAFA) Enters $50,000,000 Ceftriaxone Market and Signs Long-Term National and Regional Distribution Contracts
June 06, 2013 09:18 ET
|
Rafarma Pharmaceuticals, Inc.
SANDY, Utah, June 6, 2013 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. (the "Company") (Pink Sheets:RAFA) announces commencement of production of the antibiotic Ceftriaxone.
Ceftriaxone treats...